From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||146.4 kg/mol|
|NY (what is this?)|
Dalotuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
Dalotuzumab was developed by Merck & Co., Inc.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab" (PDF). American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|